Loading stock data…
XOMA Royalty Corporation (XOMA)
$42.15
After Hours$42.15+0.00 (+0.00%)· Last close Jun 29
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
XOMA Royalty Corporation in the Healthcare sector is trading at $42.15 with a market capitalization of $523M. Wall Street consensus targets $39.00 (1 analysts), implying a -7.5% move over the next 12 months. The stock is currently near its 52-week high of $42.81, remaining 26.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -7.5% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $310,000↓ | $1.43M↑ | $532,000↓ | $5.38M↑ | $4.32M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$480,000↓ | $2.18M↑ | -$1.33M↓ | $4.60M↓ | $5.93M |
| Net Income | $4.46M↓ | $6.10M↓ | $14.05M↑ | $9.19M↑ | $2.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$522.96M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.95%
Volume
Today's trading volume
366,860
Recent News
XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition
The fair value price target for XOMA Royalty has been reset from US$65.75 to US$39.00, now aligned with the agreed all cash acquisition price. Analysts are centering their narratives on this US$39 level as the key reference point for both valuation and deal related risk, which is shaping how they frame upside and downside from here. As you read on, you will see how this updated target fits into the evolving story around XOMA Royalty and what to watch as the transaction process moves...
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?